Every material Form 8-K Edwards Lifesciences filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edwards Lifesciences said its Chief Financial Officer, Scott Ullem, has decided to transition from his role by mid-year 2026. The company is starting a search for a new CFO, and Ullem will stay on in an advisory role after the successor is appointed.
Scott Ullem, CFO, informed the company of his decision on October 30, 2025
Transition is planned for no later than mid-year 2026
Company is initiating a selection process to appoint a new CFO
Ullem will continue in an advisory role after a new CFO is appointed
Edwards Lifesciences reported third-quarter 2025 sales of $1.55 billion, up 14.7% from a year earlier, and raised its full-year sales growth and adjusted EPS guidance. GAAP earnings per share fell to $0.50 from $0.61, and adjusted EPS was $0.67, matching the prior year, so shareholders receive higher sales expectations alongside lower reported profit.
Q3 sales were $1.55 billion, up 14.7% (12.6% adjusted); TAVR sales were $1.15 billion, up 12.4%.
GAAP diluted EPS was $0.50 versus $0.61 a year earlier; adjusted diluted EPS was $0.67 in both periods.
Full-year 2025 sales growth guidance rose to the high end of 9% to 10%; adjusted EPS guidance is $2.56 to $2.62, up from the high end of $2.45 to $2.55.
Q3 included $90.4 million in certain litigation expenses and a $40.0 million intangible assets impairment charge.
Edwards Lifesciences said Larry L. Wood, Corporate Vice President and Group President for Transcatheter Aortic Valve Replacement and Surgical Structural Heart, will resign effective September 1, 2025 to take a senior role at a company outside cardiovascular. Daniel J. Lippis, currently Corporate Vice President for Japan, Greater China and Asia Pacific, will take over as Corporate Vice President responsible for Transcatheter Aortic Valve Replacement on the same date.
Larry L. Wood notified the board on July 21, 2025 of his resignation
Resignation takes effect September 1, 2025
Daniel J. Lippis will assume responsibility for Transcatheter Aortic Valve Replacement
The filing does not disclose a replacement for Lippis's Japan, Greater China and Asia Pacific role
Edwards Lifesciences reported second-quarter 2025 sales of $1.53 billion, up 11.9% from a year earlier, and adjusted EPS of $0.67. The company raised its full-year 2025 sales growth guidance to 9% to 10% and its adjusted EPS outlook to the high end of $2.40 to $2.50. GAAP net income attributable to Edwards fell to $333.2 million from $366.3 million, partly due to a $47.1 million impairment loss.
Q2 sales $1.53 billion, up 11.9%; TAVR sales $1.1 billion, up 8.9%; TMTT sales $134.5 million, up 61.9%
Full-year 2025 sales guidance raised to 9% to 10%, or $5.9 billion to $6.1 billion; TAVR sales guidance raised to $4.3 billion to $4.5 billion
Adjusted diluted EPS $0.67 in Q2; full-year adjusted EPS now expected at the high end of $2.40 to $2.50
Q2 GAAP diluted EPS $0.56 versus $0.61 a year earlier, including a $47.1 million loss on impairment
At its annual meeting on May 8, 2025, Edwards Lifesciences stockholders elected nine director nominees, approved an advisory vote on named executive officer compensation, and ratified PricewaterhouseCoopers LLP as auditor for fiscal 2025. Stockholders also approved increases to the share reserves of the company's U.S. and international employee stock purchase plans.
U.S. ESPP share reserve increased by 4,200,000 shares; International ESPP increased by 1,460,000 shares
Executive pay advisory vote approved: 412,893,480.47 for and 56,265,224.07 against
PricewaterhouseCoopers LLP ratified as independent auditor for the year ending December 31, 2025: 447,661,338.99 for and 49,958,008.47 against
Edwards Lifesciences reported first-quarter 2025 sales of $1.41 billion, up 6.2% from a year earlier, and GAAP earnings per share from continuing operations of $0.62, up from $0.54. The company raised its 2025 total sales guidance to $5.7 to $6.1 billion and its TMTT sales guidance to $530 million to $550 million, while reaffirming adjusted EPS guidance of $2.40 to $2.50. Management said operating margin is expected to face pressure from the weaker dollar, announced tariffs and the expected JenaValve acquisition close.
Q1 sales were $1.41 billion, up 6.2%; TMTT sales rose 58% to $115 million.
GAAP diluted EPS from continuing operations was $0.62 versus $0.54 a year earlier; adjusted EPS was $0.64.
2025 total sales guidance raised to $5.7 to $6.1 billion; adjusted EPS guidance of $2.40 to $2.50 reaffirmed.
Q2 2025 outlook: total sales of $1.45 to $1.53 billion and adjusted EPS of $0.59 to $0.65.
Edwards Lifesciences reported fourth-quarter 2024 results on February 11, 2025, with net sales up 9% to $1.39 billion and GAAP diluted EPS of $0.58, compared with $0.55 a year earlier. The company reiterated its 2025 sales and adjusted EPS guidance and gave first-quarter 2025 projections, so the results and outlook are steady for shareholders.
Q4 2024 net sales were $1,385.8 million, up from $1,266.4 million a year earlier.
Q4 2024 GAAP diluted EPS was $0.58 versus $0.55; adjusted diluted EPS was $0.59.
2025 guidance reiterated: constant currency sales growth of 8% to 10% and adjusted EPS of $2.40 to $2.50.
Q1 2025 outlook: total sales of $1.35 billion to $1.43 billion and adjusted EPS of $0.58 to $0.64.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edwards Lifesciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →